Treace Medical reported Q4 2025 revenue of USD 62.5 million (-9.0%), with gross profit of USD 50.4 million and gross margin of 80.6%. Q4 2025 net loss was USD 9.4 million and adjusted EBITDA was USD 6.2 million. For FY 2025, Treace Medical posted revenue of USD 212.7 million (+2.0%), gross profit of USD 169.8 million and gross margin of 79.8%, with a net loss of USD 59.0 million and adjusted EBITDA loss of USD 3.9 million. Cash, cash equivalents and marketable securities were USD 48.4 million at Dec. 31, 2025, and the company reported FY 2025 cash usage of USD 27.3 million (-46.0%). Operationally, Treace Medical added 202 net new active surgeons in FY 2025 to reach 3,337 active surgeons, and said Q4 case volume growth improved versus Q3, driven by demand for its 3D bunion correction systems. The company also reported its global patent portfolio expanded to 135 granted patents plus 199 pending applications, and said Q4 revenue was impacted by a shift in product sales toward lower priced bunion kits. Treace Medical initiated FY 2026 revenue guidance of USD 200.0 million to USD 212.0 million and expects an adjusted EBITDA loss of USD 4.0 million to USD 6.0 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Treace Medical Concepts Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602270705PRIMZONEFULLFEED9662622) on February 27, 2026, and is solely responsible for the information contained therein.